Pastori, Daniele, Ames, Paul RJ, Triggiani, Massimo, Ciampa, Antonio, Cammisotto, Vittoria, Carnevale, Roberto, Pignatelli, Pasquale, Bucci, Tommaso 
ORCID: 0000-0003-2895-6234, Iannaccone, Luigi, Marottoli, Vincenzo et al (show 7 more authors)
(2021)
Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study.
JOURNAL OF CLINICAL MEDICINE, 10 (14).
3180-.
|
PDF
Antiphospholipid Antibodies and Heart Failure with Preserved Ejection Fraction. The Multicenter ATHERO-APS Study. .pdf - Published version Download (271kB) | Preview |
Abstract
<h4>Background</h4>The prevalence of heart failure with preserved ejection fraction (HFpEF) in patients with antiphospholipid syndrome (APS) is unknown.<h4>Methods</h4>A prospective multicenter cohort study including 125 patients was conducted: 91 primary APS (PAPS), 18 APS-SLE, and 16 carriers. HFpEF was diagnosed according to the 2019 European Society of Cardiology criteria: patients with ≥5 points among major and minor functional and morphological criteria including NT-ProBNP > 220 pg/mL, left atrial (LA) enlargement, increased left ventricular filling pressure.<h4>Results</h4>Overall, 18 (14.4%) patients were diagnosed with HFpEF; this prevalence increased from 6.3% in carriers to 13.2% in PAPS and 27.8% in APS-SLE. Patients with HFpEF were older and with a higher prevalence of hypertension and previous arterial events. At logistic regression analysis, age, arterial hypertension, anticardiolipin antibodies IgG > 40 GPL (odds ratio (OR) 3.43, 95% confidence interval (CI) 1.09-10.77, <i>p</i> = 0.035), anti β-2-glycoprotein-I IgG > 40 GPL (OR 5.28, 1.53-18.27, <i>p</i> = 0.009), lupus anticoagulants DRVVT > 1.25 (OR 5.20, 95% CI 1.10-24.68, <i>p</i> = 0.038), and triple positivity (OR 3.56, 95% CI 1.11-11.47, <i>p</i> = 0.033) were associated with HFpEF after adjustment for age and sex. By multivariate analysis, hypertension (OR 19.49, 95% CI 2.21-171.94, <i>p</i> = 0.008), age (OR 1.07, 95% CI 1.00-1.14, <i>p</i> = 0.044), and aβ2GPI IgG > 40 GPL (OR 8.62, 95% CI 1.23-60.44, <i>p</i> = 0.030) were associated with HFpEF.<h4>Conclusion</h4>HFpEF is detectable in a relevant proportion of APS patients. The role of aPL in the pathogenesis and prognosis of HFpEF needs further investigation.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | antiphospholipid syndrome, HFpEF, echocardiography, heart failure |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 25 Oct 2022 14:50 |
| Last Modified: | 02 Feb 2024 11:52 |
| DOI: | 10.3390/jcm10143180 |
| Open Access URL: | https://doi.org/10.3390/jcm10143180 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3165751 |
Dimensions
Dimensions
